Highlight
High risk neuroblastoma: A persistent therapeutic challenge
Alberto Garaventa MD,
Giorgio Perilongo MD,
Alberto Garaventa MD
Division of Haematology-Oncology, Hospital “Giannina Gaslini”, Genova-Quarto, Italy
Search for more papers by this authorCorresponding Author
Giorgio Perilongo MD
Department of Pediatrics, University of Padua, Padua, Italy
Department of Pediatrics, University of Padua, Via Giustiniani 3, 35128 Padua, Italy.===Search for more papers by this authorAlberto Garaventa MD,
Giorgio Perilongo MD,
Alberto Garaventa MD
Division of Haematology-Oncology, Hospital “Giannina Gaslini”, Genova-Quarto, Italy
Search for more papers by this authorCorresponding Author
Giorgio Perilongo MD
Department of Pediatrics, University of Padua, Padua, Italy
Department of Pediatrics, University of Padua, Via Giustiniani 3, 35128 Padua, Italy.===Search for more papers by this authorNo abstract is available for this article.
REFERENCES
- 1 De Bernardi B, Carli M, Casale F, et al. Standard-dose and high-dose peptichemio and cisplatin in children with disseminated poor-risk neuroblastoma: Two studies by the Italian Cooperative Group for Neuroblastoma. J Clin Oncol 1992; 10: 1870–1878.
- 2 Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial; European Neuroblastoma Study Group; Children's Cancer and Leukaemia Group (CCLG formerly United Kingdom Children's Cancer Study Group). Lancet Oncol 2008; 9: 247–256.
- 3 de Kraker J, Hoefnagel KA, Verschuur AC, et al. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage neuroblastoma patients over 1 year of age. J Cancer 2008; 44: 551–556. Epub 2008 February 11.
- 4 Kushner BH, Kramer K, LaQuaglia MP, et al. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 2004; 22: 4888–4892.
- 5 George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: Long-term survival update. J Clin Oncol 2006; 24: 2891–2896.
- 6 Zage PE, Kletzel M, Murray K, et al. Outcomes of the POG 9340/9341/9342 Trials for Children with High-Risk Neuroblastoma: A report from children's oncology group. Ped Blood Cancer 2008 Aug 14 [Epub ahead of print].
- 7 Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165–1173.
- 8 Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 2007; 25: 67–77.
- 9 Croce M, Meazza R, Orengo AM, et al. Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen. Cancer Immunol Immunother 2008; 57: 1625–1634.
- 10 Rössler J, Taylor M, Geoerger B, et al. Angiogenesis as a target in neuroblastoma. Eur J Cancer 2008; 66: 1645–1656.
- 11 Brignole C, Marimpietri D, Pastorino F, et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. Natl Cancer Inst 2006; 98: 1142–1157.
- 12 Deubzer HE, Ehemann V, Westermann F, et al. Histone deacetylase inhibito Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells. Int J Cancer 2008; 122: 1891–1900.
- 13 Sartelet H, Oligny LL, Vassal G. AKT pathway in neuroblastoma and its therapeutic implication. Expert Rev Anticancer Ther 2008; 8: 757–769.
- 14 Hansford LM, McKee AE, Zhang L, et al. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 2007; 67: 11234–11243.
- 15 Das B, Tsuchida R, Malkin D, et al. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side-population fraction. Stem Cells 2008; 26: 1818–1830.
